Protalix Biotherapeutics Receives Research Grant of over $6 Million from the Israeli Government’s Office of the Chief Scientist

Published: Mar 11, 2009

CARMIEL, Israel--(BUSINESS WIRE)--Protalix BioTherapeutics, Inc. (NYSE Alternext US:PLX), announced today that the Office of the Chief Scientist (“OCS”) of Israel's Ministry of Industry, Trade and Labor has awarded a grant of over $6 million to the Company for calendar year 2009. The OCS awarded the grant to the Company to promote the advancement of the Company’s clinical and preclinical drug development programs.

Back to news